ClinicalTrials.Veeva

Menu
C

Clinvest Headlands, LLC | Springfield, MO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3841136
LY3549492
Ixekizumab
Rimegepant
Peresolimab
Orforglipron
LY3857210
Metformin
LY3305677

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 12 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3549492

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

The main purpose of this study is to assess the safety and efficacy of peresolimab in adult participants with moderately-to-severely active rheumatoi...

Active, not recruiting
Joint Diseases
Arthritis
Drug: Peresolimab
Drug: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136
Locations recently updated

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks.Rimege...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 recep...

Active, not recruiting
Obesity
Muscle Loss
Drug: Semaglutide
Drug: Enobosarm
Locations recently updated

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Enrolling
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

Trial sponsors

Lilly logo
Moderna logo
Pfizer logo
Veru logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems